Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Phase 4
500
about 7.5 years
6–17
4 sites in FL, NY, OH +1
What this study is about
This trial is testing how genetic variations in carboxylesterase 1 (CES1) affect the way methylphenidate (MPH), a medication, works in children with ADHD. The goal is to find out if certain CES1 genes are linked to how MPH affects people with ADHD.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Methylphenidate
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
methylphenidate (CNS stimulant; blocks reuptake of dopamine and norepinephrine)
oral (Disintegrating Oral Tablet)
Primary: Maximum methylphenidate plasma concentration (Cmax),
Secondary: Time to maximum concentration (Tmax)
Psychiatry / Mental Health